Wollenberg A, Nakahara T, Maari C, et al. - Among patients with moderate-to-severe atopic dermatitis (AD) previously showing inadequate response to topical corticosteroids (TCS), this investigation was carried out to assess the influence of baricitinib plus background TCS on health-related quality of life (HRQoL), to determine the impact of AD symptoms on work productivity and life functioning, and treatment benefit using patient-reported outcome assessments. In a Phase 3, multicentre, double-blind trial (BREEZE-AD7), adult patients suffering from AD were randomly assigned 1 : 1 : 1 to daily oral placebo (control) or baricitinib 4- or 2-mg plus TCS. Overall 329 patients were randomised. According to findings, not only significant improvements in treatment benefit, at Week 16, were conferred by baricitinib plus TCS but also rapid significant improvements in HRQoL as well as impact of AD symptoms on work productivity and functioning through 16 weeks were provided when compared with placebo plus TCS.